Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP study of solriamfetol for cognitive function in obstructive sleep apnea with excessive daytime sleepiness
2020-004243-92Phase 4Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change in DSST average score. Started Apr 2021; status: terminated.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2020-004243-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004243-92.